

## PEDIATRIC EMPIRIC ANTIMICROBIAL GUIDE 2016

*This guide does NOT apply to NICU or immunocompromised patients.*

**A thorough clinical assessment is required to identify any complicating factors which may necessitate alternative/additional therapy**  
**Selection of empiric regimens may need to be tailored according to current local antibiogram or individual clinical factors.**

starting anti-microbial therapy, take blood/urine/CSF and/or other relevant samples for culture wherever possible. Obtain appropriate dosage from current "[Drug Dosage Guidelines](#)". Consider the need for dose adjustments (e.g. renal impairment) and age-related contraindications for antimicrobials. Caution for use in neonates under 44 weeks corrected gestational age.

**REVIEW DAILY - Adjust treatment according to microbiologic results as soon as they become available.**

**Consult ID and/or relevant subspecialty team(s) if required**

*All drugs IV unless stated*

Infection	Most likely pathogens	First choice	Penicillin allergy <sup>^</sup>	Refs**
<b>Sepsis - unknown source</b>				
Sepsis (<4 weeks)	<i>Streptococcus agalactiae</i> (GBS) <i>Escherichia coli</i> <i>Listeria monocytogenes</i> Herpes simplex virus (HSV)	Ampicillin + (Gentamicin or Cefotaxime) ± Acyclovir	Vancomycin + (Gentamicin or Cefotaxime) ± Acyclovir	<a href="#">BCCH</a> <a href="#">AAP</a> <a href="#">SSC</a>
Sepsis (≥4 weeks)	<i>Neisseria meningitidis</i> <i>Streptococcus pneumoniae</i> <i>Escherichia coli</i> <i>Staphylococcus aureus</i>	Cefotaxime <sup>‡</sup> ± Vancomycin*	Cefotaxime <sup>‡</sup> ± Vancomycin	<a href="#">BCCH</a> <a href="#">SSC</a>
<b>CNS</b>				
Meningitis (<4 weeks)	<i>Streptococcus agalactiae</i> (GBS) <i>Escherichia coli</i> <i>Listeria monocytogenes</i> Herpes simplex virus (HSV)	Ampicillin + Cefotaxime + Acyclovir	Vancomycin + Cefotaxime ± Acyclovir	<a href="#">AAP</a> <a href="#">IDSA</a>
Meningitis (≥4 weeks)	<i>Neisseria meningitidis</i> <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i>	Cefotaxime <sup>‡</sup> + Vancomycin ± Acyclovir	Cefotaxime <sup>‡</sup> + Vancomycin ± Acyclovir	<a href="#">IDSA</a> <a href="#">CPS</a>
Encephalitis	Herpes simplex virus (HSV)	Acyclovir + Antibiotics as for "Meningitis"	Acyclovir + Antibiotics as for "Meningitis"	<a href="#">IDSA</a>
Cerebral abscess or subdural empyema	<i>Streptococcus</i> spp. <i>Staphylococcus aureus</i> Anaerobic organisms Gram-negative organisms <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i>	Cefotaxime <sup>‡</sup> + Vancomycin + Metronidazole	Cefotaxime <sup>‡</sup> + Vancomycin + Metronidazole	<a href="#">FC</a>
<b>ENT, ocular and dental</b>				
Streptococcal pharyngitis / tonsillitis	<i>Streptococcus pyogenes</i> (Group A Strep)	Penicillin V PO or Amoxicillin PO or Penicillin G	Cephalexin PO or Clindamycin PO or Clarithromycin PO or Cefazolin	<a href="#">IDSA</a> <a href="#">RB</a>
Bacterial acute otitis media	<i>Haemophilus influenzae</i> <i>Streptococcus pneumoniae</i> <i>Moraxella catarrhalis</i>	Amoxicillin PO or Amoxicillin-clavulanate PO	Cefprozil PO or Clarithromycin PO	<a href="#">CPS</a> <a href="#">AAP</a>
Mastoiditis	<i>Streptococcus pneumoniae</i> <i>Streptococcus pyogenes</i> (Group A Strep) <i>Staphylococcus aureus</i>	Cefotaxime <sup>‡</sup> ± Vancomycin	Cefotaxime <sup>‡</sup> ± Vancomycin	<a href="#">FC</a>
Sinusitis	<i>Haemophilus influenzae</i> <i>Streptococcus pneumoniae</i> <i>Moraxella catarrhalis</i> <i>Staphylococcus aureus</i> <i>Streptococcus pyogenes</i> (Group A Strep) Anaerobic organisms (older children)	Amoxicillin PO or Amoxicillin-clavulanate PO If IV treatment required, treat as for mastoiditis	Cefprozil PO or Clarithromycin PO or Cefixime PO + Clindamycin PO  If IV treatment required, treat as for mastoiditis	<a href="#">IDSA</a> <a href="#">AAP</a> <a href="#">BD</a> <a href="#">CFM</a>
Cervical lymphadenitis	<i>Staphylococcus aureus</i> <i>Streptococcus pyogenes</i> (Group A Strep)	Cephalexin PO or Clindamycin PO* or Cefazolin	Clindamycin PO or Cefazolin	<a href="#">BD</a> <a href="#">FC</a>
Preseptal cellulitis	<i>Streptococcus pneumoniae</i> <i>Staphylococcus aureus</i>	Cephalexin PO or Clindamycin PO* or Cefazolin or Vancomycin*	Cefprozil PO or Clindamycin PO* or Cefazolin or Vancomycin*	<a href="#">AAP</a> <a href="#">Long</a>
Orbital cellulitis	<i>Staphylococcus aureus</i> <i>Streptococcus pneumoniae</i> Other <i>Streptococcus</i> spp. <i>Haemophilus influenzae</i>	Cefotaxime <sup>‡</sup> ± Vancomycin	Cefotaxime <sup>‡</sup> ± Vancomycin	<a href="#">AAP</a> <a href="#">Long</a>

<sup>^</sup>Avoid all beta-lactam antibiotics (i.e. cephalosporins, carbapenems) if anaphylaxis to penicillins - **consult ID; consider allergy assessment.**

Pediatric empiric antimicrobial therapy. Version 4.1 updated September 29, 2016 by the PHSA Antimicrobial Stewardship Program

Approved by: BCCH ID, Micro, All Divisions within UBC Department of Pediatrics

Reviewed by the Provincial Antimicrobial Clinical Expert Group – September 2016

**All drugs IV unless stated**

Infection	Most likely pathogens	First choice	Penicillin allergy <sup>^</sup>	Refs**
Dental abscess with fever and/or extensive spread	Viridans streptococci <i>Peptostreptococcus</i> spp. <i>Prevotella</i> spp. <i>Porphyromonas melaninogenicus</i> <i>Fusobacterium</i> spp. <b>Usually polymicrobial</b>	Amoxicillin-clavulanate PO or Penicillin G + Metronidazole PO	Clindamycin PO/IV	<a href="#">BD</a> <a href="#">FC</a>
<b>Lower respiratory tract</b>				
Community-acquired pneumonia (<1 month)	<i>Streptococcus agalactiae</i> (GBS) <i>Escherichia coli</i> <i>Listeria monocytogenes</i>	Ampicillin + (Gentamicin or Cefotaxime <sup>†</sup> )	Cefotaxime <sup>†</sup> + Gentamicin + Vancomycin	BCCH <a href="#">BD</a>
Community-acquired pneumonia (1-3 months)	<i>Streptococcus pneumoniae</i> <i>Streptococcus agalactiae</i> (GBS) <i>Staphylococcus aureus</i> <i>Escherichia coli</i> <i>Chlamydia trachomatis</i>	Cefotaxime <sup>†</sup> ± Vancomycin ± Clarithromycin PO	Cefotaxime <sup>†</sup> ± Vancomycin ± Clarithromycin PO	BCCH <a href="#">BD</a>
Community-acquired pneumonia (>3 months) - mild	Respiratory viruses <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i> <i>Staphylococcus aureus</i> <i>Mycoplasma pneumoniae</i> <i>Chlamydia pneumoniae</i>	Amoxicillin PO	Cefprozil PO	<a href="#">IDSA</a> <a href="#">CPS</a>
Community-acquired pneumonia (>3 months) - moderate		Ampicillin ± Clarithromycin PO ± Oseltamivir PO	Cefotaxime ± Clarithromycin PO ± Oseltamivir PO	<a href="#">AAP</a> <a href="#">IDSA</a> <a href="#">CPS</a> BCCH
Community-acquired pneumonia (>3 months) - severe		Cefotaxime <sup>†</sup> ± Vancomycin ± Clarithromycin PO ± Oseltamivir PO	Cefotaxime <sup>†</sup> + Vancomycin ± Clarithromycin PO ± Oseltamivir PO	<a href="#">IDSA</a> <a href="#">CPS</a> <a href="#">BCCH</a>
Parapneumonic empyema	<i>Staphylococcus aureus</i> <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i>	Cefotaxime <sup>†</sup> ± Vancomycin	Cefotaxime <sup>†</sup> ± Vancomycin	<a href="#">CPS</a> <a href="#">IDSA</a> BCCH
Hospital-acquired pneumonia	<i>Staphylococcus aureus</i> <i>Haemophilus influenzae</i> <i>Enterobacter</i> spp. <i>Pseudomonas aeruginosa</i>	(Cefotaxime <sup>†</sup> or Piperacillin-tazobactam) ± Vancomycin*	Cefotaxime <sup>†</sup> ± Vancomycin ± Gentamicin	BCCH <a href="#">IDSA</a>
Aspiration pneumonia	<i>Staphylococcus aureus</i> <i>Haemophilus influenzae</i> <i>Enterobacter</i> spp. Oral anaerobes (see "dental abscess")	Amoxicillin-clavulanate PO or Cefuroxime PO + (Metronidazole or Clindamycin IV/PO)	Cefotaxime <sup>†</sup> + Clindamycin IV/PO or C PO + (Metronidazole or Clindamycin IV/PO)	<a href="#">Mandell</a>
<b>Cardiac</b>				
Infective endocarditis	Viridans streptococci <i>Staphylococcus aureus</i>	As guided by blood culture results <b>Consult ID &amp; Cardiology</b>	As guided by blood culture results <b>Consult ID &amp; Cardiology</b>	<a href="#">AHA</a>
<b>Genito-urinary tract</b>				
Urinary tract infection (<2 months)	<i>Escherichia coli</i> <i>Klebsiella</i> spp. <i>Proteus</i> spp. <i>Enterobacter</i> spp. <i>Enterococcus</i> spp.	Ampicillin + Gentamicin Imperative to check blood and CSF cultures. If positive, exit UTI pathway.	Cefotaxime or Gentamicin Imperative to check blood and CSF cultures. If positive, exit UTI pathway.	<a href="#">AAP</a> <a href="#">CPS</a>
Urinary tract infection – mild (≥2 months)	<i>Escherichia coli</i> <i>Klebsiella</i> spp. <i>Proteus</i> spp. <i>Enterobacter</i> spp. <i>Enterococcus</i> spp. <i>Staphylococcus saprophyticus</i> (adolescents)	Cephalexin PO	Cephalexin PO	<a href="#">AAP</a> <a href="#">BD</a> <a href="#">CPS</a>
Urinary tract infection – severe (≥2 months)	<i>Escherichia coli</i> <i>Klebsiella</i> spp. <i>Proteus</i> spp. <i>Enterobacter</i> spp.	Cefotaxime or Gentamicin	Cefotaxime or Gentamicin	<a href="#">AAP</a> <a href="#">CPS</a>
Pelvic inflammatory disease	<i>Neisseria gonorrhoeae</i> <i>Chlamydia trachomatis</i> Anaerobic organisms	(Cefixime PO or Ceftriaxone IM) + Doxycycline PO ± Metronidazole PO	(Cefixime PO or Ceftriaxone IM) + Doxycycline PO ± Metronidazole PO	<a href="#">BD</a> <a href="#">BCCDC</a> <a href="#">RB</a>
<b>Intra-abdominal</b>				
Bacterial gastroenteritis	<i>Salmonella</i> spp. <i>Shigella</i> spp. <i>Campylobacter</i> spp. <i>Escherichia coli</i> <i>Plesiomonas shigelloides</i> <i>Aeromonas hydrophila</i>	Treatment not routinely required. If severe then treat according to susceptibilities of organism isolated	Treatment not routinely required. If severe then treat according to susceptibilities of organism isolated	<a href="#">IDSA</a>
Secondary peritonitis (excluding peritoneal dialysis patients)	<i>Escherichia coli</i> <i>Klebsiella</i> spp. <i>Pseudomonas aeruginosa</i> <i>Enterococcus</i> spp. <i>Bacteroides fragilis</i> <i>Peptostreptococcus</i> spp.	Piperacillin-tazobactam or Ampicillin + Gentamicin + Metronidazole	Cefotaxime <sup>†</sup> + Metronidazole	<a href="#">IDSA</a>
Primary peritonitis	<i>Streptococcus pneumoniae</i> <i>Escherichia coli</i>	Cefotaxime <sup>†</sup>	Cefotaxime <sup>†</sup>	<a href="#">FC</a> <a href="#">Mandell</a>

<sup>^</sup>Avoid all beta-lactam antibiotics (i.e. cephalosporins, carbapenems) if anaphylaxis to penicillins - **consult ID; consider allergy assessment.**

Pediatric empiric antimicrobial therapy. Version 4.1 updated September 29, 2016 by the PHSA Antimicrobial Stewardship Program

**Approved by:** BCCH ID, Micro, All Divisions within UBC Department of Pediatrics

**Reviewed by** the Provincial Antimicrobial Clinical Expert Group - September 2016

**All drugs IV unless stated**

Infection	Most likely pathogens	First choice	Penicillin allergy <sup>^</sup>	Refs**
Ascending cholangitis	<i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Enterobacter</i> spp. <i>Pseudomonas aeruginosa</i> <i>Enterococcus</i> spp. Anaerobic organisms	Ampicillin + Cefotaxime <sup>‡</sup> ± Metronidazole or Piperacillin-tazobactam	Vancomycin ± Cefotaxime <sup>‡</sup> ± Metronidazole	<a href="#">FC</a> <a href="#">Long</a>
Antibiotic-associated colitis ( <i>Clostridium difficile</i> infection)	<i>Clostridium difficile</i>	Metronidazole PO <b>Stop all other antibiotics if possible</b>	Metronidazole PO <b>Stop all other antibiotics if possible</b>	<a href="#">BCCH</a> <a href="#">IDSA</a> <a href="#">CPS</a>
<b>Skin and soft tissue</b>				
Cellulitis - mild	<i>Streptococcus pyogenes</i> (Group A Strep) <i>Staphylococcus aureus</i>	Cephalexin PO or Trimethoprim-Sulfamethoxazole PO*	Cephalexin PO or Trimethoprim-Sulfamethoxazole PO*	<a href="#">IDSA</a> <a href="#">CPS</a>
Cellulitis - severe	<i>Streptococcus pyogenes</i> (Group A Strep) <i>Staphylococcus aureus</i>	Cefazolin ± Clindamycin PO*	Cefazolin ± Clindamycin PO*	<a href="#">IDSA</a> <a href="#">BD</a>
Soft tissue injury - clean	Not infected	Not required	Not required	<a href="#">FC</a>
Dog / cat / human bites - mild	<i>Staphylococcus aureus</i> <i>Streptococcus</i> spp. <i>Eikenella corrodens</i> (human) <i>Pasteurella</i> spp. (dog/cat) <i>Capnocytophaga cynodegmi</i> (dog/cat) Anaerobic organisms <b>Usually polymicrobial</b>	Amoxicillin-clavulanate PO	Clindamycin PO* +Trimethoprim-Sulfamethoxazole PO*	<a href="#">IDSA</a> <a href="#">FC</a>
Dog / cat / human bites - severe	<i>Staphylococcus aureus</i> <i>Streptococcus</i> spp. <i>Eikenella corrodens</i> (human) <i>Pasteurella</i> spp. (dog/cat) <i>Capnocytophaga cynodegmi</i> (dog/cat) Anaerobic organisms <b>Usually polymicrobial</b>	Piperacillin-tazobactam	Clindamycin* +Trimethoprim-Sulfamethoxazole*	<a href="#">IDSA</a> <a href="#">FC</a> <a href="#">Mandell</a>
Necrotising fasciitis (unknown etiology)	<i>Streptococcus pyogenes</i> (Group A Strep) <i>Staphylococcus aureus</i> Aerobic and Anaerobic organisms <b>May be polymicrobial</b>	Piperacillin-tazobactam + Vancomycin + Clindamycin	Ciprofloxacin + Vancomycin + Clindamycin	<a href="#">IDSA</a> <a href="#">FC</a>
Documented group A streptococcal necrotising fasciitis	<i>Streptococcus pyogenes</i> (Group A Strep)	Penicillin + Clindamycin	Cefotaxime <sup>‡</sup> + Clindamycin	<a href="#">IDSA</a> <a href="#">FC</a>
<b>Musculoskeletal</b>				
Osteomyelitis or septic arthritis (≥3 months)	<i>Staphylococcus aureus</i> <i>Streptococcus pyogenes</i> (Group A Strep) <i>Streptococcus pneumoniae</i> <i>Kingella kingae</i> <i>Neisseria</i> spp. <i>Salmonella</i> spp.	Cefazolin or Vancomycin*	Cefazolin or Vancomycin*	<a href="#">FC</a> <a href="#">Mandell</a>

‡ Cefotaxime may be interchanged with ceftriaxone for children over 30 days old and not on calcium-containing parenteral products (e.g. TPN).

\*As anti-MRSA agent. **Current local MRSA rates are available via the [hospital antibiogram](#).** The following factors have been associated with MRSA in previous studies:

- Previous known MRSA infection in child or a significant contact (e.g. family member)
- Family member is a healthcare worker
- First nations child or Pacific Island origin (e.g. Samoan)
- Day care attendance
- Prolonged hospitalization in the last 1 year
- Antibiotic therapy in the last 2 months
- Critically ill
- (Chronic skin condition, e.g. atopic eczema)

\*\*References:

- [AAP = American Academy of Pediatrics Guidelines](#)
- [BCCDC = BC Centre for Disease Control](#)
- [BCCH = Pre-existing BC Children's Hospital Guidelines \(sepsis guideline, PICU guideline\)](#)
- [BD = Bugs & Drugs. Blondel-Hill and Fryters \(2012\)](#)
- [CFM = Canadian Family Physician, by the College of Family Physicians of Canada](#)
- [CPS = Canadian Pediatric Society Guidelines](#)
- [IDSA = Infectious Diseases Society of America Guidelines](#)
- [RB = Red book. American Academy of Pediatrics \(2015\)](#)
- [FC = Textbook of Pediatric Infectious Diseases. Feigin and Cherry, 7th ed. \(2014\)](#)
- [Mandell = Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8<sup>th</sup> ed. \(2015\)](#)
- [Long = Principles and Practice of Pediatric Infectious Diseases. Long, Pickering and Prober, 4th ed. \(2012\)](#)
- [SSC = Surviving Sepsis Campaign: International Guidelines for the Management of Severe Sepsis and Septic Shock: 2012](#)

<sup>^</sup>Avoid all beta-lactam antibiotics (i.e. cephalosporins, carbapenems) if anaphylaxis to penicillins - **consult ID; consider allergy assessment.**

Pediatric empiric antimicrobial therapy. Version 4.1 updated September 29, 2016 by the PHSA Antimicrobial Stewardship Program

**Approved by:** BCCH ID, Micro, All Divisions within UBC Department of Pediatrics

**Reviewed by** the Provincial Antimicrobial Clinical Expert Group - September 2016